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Optimize Outcomes
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Abstract
Survival to discharge in patients presenting with cardiogenic shock who are 
managed using extracorporeal membrane oxygenation (ECMO) remains low at 
~50%. This speaks to the acuity and severity of individuals being placed on ECMO, 
as well as the time dependent risk for complications associated with this therapy. 
Although some patients are able to be weaned from ECMO to either recovery, left 
ventricular assist device or heart transplantation, other individuals do not survive 
after device removal, suggesting that current protocols may not be identifying 
individuals with enough intrinsic cardiac recovery to maintain adequate end-organ 
perfusion. The decision to wean an individual from ECMO is complex and entails 
several factors that are dynamic and evolving daily while on full circulatory sup-
port. Objective clinical, hemodynamic and biological markers are needed to be 
controlled prior to trialing device weans but many times the decision relies on 
clinical experience and intuition. The purpose of this chapter will be to: (1) outline 
the survival and risks associated with ECMO which encourages early weaning trials 
and (2) identify patient factors related to either successful weaning or early referral 
for durable mechanical support or transplant.
Keywords: venoarterial ECMO, weaning, cardiac recovery, echocardiography, 
hemodynamics
1. Introduction
Cardiogenic shock to date remains associated with a significant mortality 
(50–80%) even after revascularization [1]. For these patients and in those with 
other forms of refractory cardiogenic shock or cardiac arrest, circulatory support 
with the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) 
has been utilized to stabilize and improve their survival. Its rapidly expanding use 
across many centers has favorably altered outcomes in severely critically ill patients 
and in many instances it serves as a bridge to decision or recovery [2]. However, 
weaning of VA-ECMO represents a significant challenge depending on the initial 
indication for its use. Moreover, there is a paucity of data on factors that predict 
weaning success from VA-ECMO and no clear guidelines to determine which 
patients will survive after device removal.
With the rapid evolving technology of short term mechanical circulatory sup-
port and the increasing number of ECMO use across many centers, there needs to 
be a clear understanding of the indications, hemodynamic impact, limitations and 
risks associated with its application to determine who will be a good candidate for 
device wean and removal.
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In this chapter we will review the basic principles of VA-ECMO function, 
predictors of survival, conditions conducive towards successful weaning and lastly, 
weaning strategies.
2. Venoarterial extracorporeal membrane oxygenation function
VA-ECMO support is a well-established technology that allows for full cardio-
pulmonary support with the goal to recover organ injury. Patients who may require 
this therapy include: refractory cardiogenic shock (CS), cardiac arrest (CA), refrac-
tory ventricular arrhythmia, acute or decompensated biventricular failure (AHF), 
pulmonary hypertension associated with right ventricular failure, fulminant 
myocarditis, and postcardiotomy cardiogenic shock (PCCS) [3].
The primary goal of VA-ECMO is restoration of tissue perfusion and avoidance 
of permanent end organ dysfunction. It has a unique hemodynamic effect due 
to its dual circulatory support circuit. The venous drainage cannula reduces flow 
through the lung vasculature, decreasing stress on the right heart while the arte-
rial outflow cannula increases flow to the systemic arterial vasculature and the 
afterload to the left ventricle proportionate to the pump speed/flow. With incre-
mental changes in speed and flow, the increased afterload reduces aortic valve 
opening and, in cases of severe left ventricular dysfunction, severe right ventricu-
lar dysfunction or asystole, the aortic valve may not open at all. The implications 
of the latter include increased LV end diastolic pressure and the development of 
pulmonary edema.
3. Venoarterial extracorporeal membrane oxygenation outcomes
VA-ECMO has been shown to increase survival to hospital discharge in patients 
with advanced heart disease with some cases having favorable long-term survival 
[4]. However, outcomes differ depending on the underlying etiology of cardiopul-
monary collapse at the time of VA-ECMO cannulation. In a large national inpatient 
database from Japan with 5263 patients receiving ECMO, the in-hospital mortality 
was 37.9%, with 64.4% weaned off the device. Cardiac arrest at the time of hospital 
presentation was recognized as the primary factor for poor survival compared to 
cardiogenic shock alone. Moreover, higher age and smaller BMI were associated 
with in hospital mortality. The majority of patients presenting with cardiogenic 
shock had underlying ischemic heart disease, followed by heart failure, valvular 
heart disease and myocarditis. Notably, the preponderance of patients discharged 
from the hospital after weaning from ECMO were those with heart failure (31.1%) 
and myocarditis (41.9%) compared to those with ischemic heart disease (20.3%). 
In-hospital mortality after weaning however remained elevated with about half of 
the patients who were weaned dying in the hospital. This high mortality suggests 
non-modifiable risk factors with persistence of critical illness even after weaning 
VA-ECMO, as well as differences in survival depending on the underlying etiol-
ogy of shock, with those having ischemic heart disease at the time of presentation 
experiencing a 79.1% in-hospital mortality [5].
In patients presenting with PCCS, VA-ECMO is a viable salvage strategy associ-
ated with increased survival to hospital discharge. In a meta-analysis of 21 studies 
with 1866 patients, survival to hospital discharge was achieved in 20.8–65.4% of 
patients placed on VA-ECMO [6]. Even more, PCCS patients undergoing VA-ECMO 
have an acceptable 5-year survival of 55.8% compared to other types of cardiogenic 
shock [7].
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These findings drastically differ to those presenting with acute myocardial 
infarction associated CS (AMI-CS) where their survival to hospital discharge 
remains low (33–59%) [8]. This could potentially be mitigated by early interven-
tion at the time of AMI-CS presentation and VA-ECMO support, specifically in 
those undergoing simultaneous revascularization. In a study of 334 patients with 
ST elevation AMI, the group that underwent early VA-ECMO support at the time 
of percutaneous intervention had a lower 30-day mortality compared to those 
without the support (30.1 vs. 41.7%) with a strong benefit in those with profound 
shock—defined as systolic blood pressure <75 mmHg despite intravenous inotropic 
agent administration and intra-aortic balloon pump (IABP) support associated with 
altered mental status and respiratory failure—compared to those without (72 vs. 
39.1% for 30-day death) [9]. Among notable predictors for 30 days mortality were 
the presence of advanced heart failure (defined as NYHA ≥ III), post intervention 
TIMI flow grade ≤2 and profound cardiogenic shock.
Lastly in those with AHF, outcomes on VA-ECMO are less promising depending 
on the original insult. For those with acute presentations, outcomes on VA-ECMO 
are more favorable compared to those with a chronic cardiomyopathy [10–12]. 
Specifically, those with fulminant myocarditis and CS or CA survival to discharge 
ranged from 60 to 88% [10], compared to only 56% in those with chronic cardio-
myopathy [11, 12]. In those with long standing heart failure though the decision 
to bridge to another salvage strategy is of paramount importance as their cardiac 
reserve is limited (characterized by low cardiac index and cardiac power) with 
77–79% requiring more advanced MCS support including durable VAD to allow for 
both short-term and long-term survival [11, 12]. Nevertheless, the high mortality 
rates in patients who receive VA-ECMO heighten the importance of limiting patient 
selection to those who can be weaned from device support.
When patients present with CS, inserting a VA-ECMO as a bridge to decision 
device allows for assessment of neurological and end-organ recovery, making 
short-term prognostication possible. In many instances, commencing support prior 
to hemodynamic deterioration and multiorgan failure or cardiac arrest can allow 
for transition to viable long-term therapies including VAD or heart transplanta-
tion. Studies have shown that in patients presenting with refractory cardiogenic 
shock requiring mechanical circulatory support, 56% survive with 26% of patients 
transitioning to an implantable VAD, 11% undergoing heart transplantation and 
18% showing cardiac recovery [12, 13].
4. Venoarterial extracorporeal membrane oxygenation complications
Although ECMO can improve survival to hospital discharge, several studies 
show significant morbidity with rates increasing with prolonged duration on sup-
port. A meta-analysis of 20 studies including 1866 patients demonstrated bleeding 
as one of the most common complications (40.8%), followed by requirement of 
dialysis (46%), significant infection (30.4%), limb ischemia (16.9%), and stroke 
(5.9%). Vascular complications, bleeding and blood transfusions were associated 
with significant in-hospital mortality [6]. Many of the complications relate to the 
vascular access site, with femoral cannulation requiring surgical intervention in 
20% of the cases [14]. A negative downstream effect of cannulation is distal isch-
emia which can lead to arterial thrombosis and gangrene. This complication can be 
mitigated by preemptively placing a small antegrade perfusion cannula to bypass 
the area of obstruction from the ECMO arterial cannula [15]. Moreover, vascular 
complications can lead to unsuccessful weaning trials as serious bleeding events 
increase the need for blood product transfusions and the incidence of thrombotic 
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events. Specifically, thrombotic events were noted to occur in 17% of patients, 
mostly as lower extremity arterial thromboses, and can impact the duration on 
support, increase morbidity and affect overall outcomes [16, 17].
LV distention in VA-ECMO. When contemplating weaning trials to assess for 
LV recovery, consideration should be taken on the loading effect that VA-ECMO 
has on the left ventricle. Proper unloading of the LV can avoid complications from 
LV distention including pulmonary edema, worsening oxygenation, increased left 
ventricular wall stress, reduced myocardial blood flow and ventricular arrhythmias. 
In fact, acute pulmonary edema in the setting of peripheral VA-ECMO has been 
associated with mortality, with many patients dying within hours after implant 
or requiring conversion to central VA-ECMO [18]. In a study of 121 patients on 
ECMO with LV distention, 16% required decompression with an Impella device and 
cardiac recovery was inversely related to the degree of LV distention. Furthermore, 
those presenting with LV distention requiring decompression had lower survival in 
the first 30 days following VA-ECMO compared to those not requiring decompres-
sion. More so, the study noted that those presenting with acute decompensated 
heart failure had a delayed LV decompression strategy which was associated lower 
survival [19]. This may suggest that more aggressive unloading is required upfront 
when clinical signs of LV distention are present. In one study, adding an Impella 
device improved 30-day survival in those presenting with AMI compared to other 
groups. Additionally, in those with cardiogenic shock due to acute decompensated 
systolic heart failure, unloading can help to stabilize and bridge them to the next 
strategy. In a series of 52 patients with ADHF, 71% required an LV venting device 
with the vast majority transitioned to a durable device support [12].
5. Factors associated with successful weaning from VA-ECMO
Determining successful weaning from VA-ECMO relies on multiple variables 
which can be partitioned into pre-implant and during support factors.
5.1 Pre-ECMO factors
Patient selection. Many risk scores have identified several variables that 
rely on clinical and biochemical markers. The SAVE score is a tool that discrimi-
nates between survivors and non-survivors of refractory cardiogenic shock on 
VA-ECMO. While younger patients, acute myocarditis, post-heart transplant, 
refractory arrhythmias and high diastolic blood pressure are protective factors, 
those with chronic renal disease, prolonged intubation, pre-ECMO organ  
failure, lower pulse pressure and lower bicarbonate are associated with poor 
survival. (http://www.save-score.com/) [20]. Similarly to SAVE, the ENCOURAGE 
survival score utilizes predictors for those presenting with CS due to AMI, however 
unlike SAVE it places more weight placed on gender, body mass index, Glasgow 
coma score and level of serum lactate. Survival was also directly proportional to 
the patient’s risk score (probabilities of survival were 80%, 58, 25, 20, and 7% for 
classes 0–12, 13–18, 19–22, 23–27, and ≥28, respectively [21].
5.2 During ECMO factors
Once VA-ECMO support is initiated, there is a very narrow window to assess 
end organ function recovery and decide on need for advanced therapies. In a cohort 
of 124 consecutive patients receiving VA-ECMO for CS, about two thirds of the 
deaths occurred during the first 4 days due to multiorgan failure, however those 
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who were supported for more than 6 days had a reduced in-hospital mortality, with 
50%, achieving successful device wean. In addition, prolonged support provided 
an opportunity for improved patient selection with 60% reaching cardiac recovery, 
26% undergoing heart transplantation and 14% ventricular assist device (VAD) 
implant. After a median follow up of 2.4 years, survival at 1 year was 78% for those 
who achieved cardiac recovery, 51% for those who underwent heart transplant and 
75% with VAD implant [18].
LV unloading. Ventricular decompression with an IABP during implant can 
allow for weaning and survival, bridge to LVAD or transplantation, while its 
non-use has been associated with increased risk for death during support or after 
VA-ECMO is withdrawn [22]. A recent meta-analysis of 17 observational studies 
comprising 3997 patients with 42% receiving an LV unloading device (IABP 92%, 
percutaneous VAD 5.5%, trans-septal left atrial cannulation 3%) showed a reduc-
tion in mortality when utilizing LV unloading devices compared to those without 
LV unloading (54 vs. 65%, RR 0.79, CI 95% 0.72–0.87). Secondary outcomes for 
limb ischemia, bleeding, need for renal replacement therapy, multiorgan failure, 
stroke or transient ischemic attack were not different among all cohorts [23].
Echocardiography. Several echocardiographic indicators exist when consider-
ing a weaning trial. Improvement in underlying LV function with an ejection 
fraction ≥35%, LV outflow tract velocity-time integral >10 cm, tissue Doppler 
peak systolic velocity of the mitral annulus ≥6 m/s, absence of LV dilatation, and 
no cardiac tamponade while on minimal support have been shown as good predic-
tors of successful weaning [24, 25]. Similarly, significant improvement in right 
ventricular function during weaning identifies greater opportunity for survival. In 
a study of 46 patients on VA-ECMO, RV ejection fraction (RVEF) was assessed by 
3D echocardiography. RV free wall strain, RV fractional area change, and central 
venous pressure were found to be independently associated with RVEF. A cutoff 
RVEF of >24.6% was found to be a predictor for weaning success after first cannula-
tion with lower values associated with increased all-cause mortality at 30 days (HR 
15.86; 95% CI, 3.56–70.73; p < 0.001) [26].
Hemodynamics parameters. Multiple hemodynamic variables have been found 
to be predictive of successful weaning. Presence of a pulse pressure greater than 
50 mmHg, elevated systolic pressure greater than 100 mmHg has been associated 
with good prognosis and survival [25]. Maintaining a perfusion mean arterial 
pressure (MAP) >60 mmHg with minimal inotropic support is critical [27]. Right 
heart catheterization data shows that a pulmonary capillary wedge pressure <24, 
PVR < 1.1 WU, mean pulmonary arterial pressure <25, transpulmonary gradient 
<10 are recommended parameters to achieve prior to a weaning trial and that ino-
tropic agents as well as pulmonary vasodilators can be of assistance during weaning 
efforts [26].
Biomarkers. Serological markers of poor perfusion have been associated with 
worse prognosis. Lactate has been recognized as a biomarker for macrovascular 
tissue perfusion and early clearance at 24 hours after VA-ECMO initiation has been 
correlated with weaning and survival [28]. Loforte et al., analyzed 228 patients 
supported on VA-ECMO primarily post-cardiotomy CS. The authors found that 
blood lactate level (>3 mmol/L) and a CK-MB index of 10% 72 hours after ECMO 
initiation, was predictive of a 50% probability of 30-day mortality [29]. An elevated 
creatinine on the day of withdrawal or weaning trial has been associated with poor 
outcome with a four-fold risk of death when the level is above 1.4 mg/dL [18].
Tissue perfusion. Derangements in the microvasculature have been noted in 
both severe sepsis as well as cardiogenic shock, with measures of microcircula-
tion emerging as new markers for tissue perfusion [30]. In those supported by 
VA-ECMO, there is observational data suggesting that preserved microcirculation 
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at time of VA-ECMO cannulation may be more specific than hemodynamic mea-
sures for identifying successful VA-ECMO weaning and survival. This discordance 
between the micro and macro-circulation has been described previously as a loss 
of hemodynamic coherence in part due to heterogeneous flow the organs receive 
during support, alterations in capillary density and presence of tissue edema [31]. 
Specifically, one study which assessed microcirculation serially, found that even 
in the presence of preserved lactate, tissue perfusion as estimated by parameters 
of microcirculation did not improve on VA-ECMO and those with compromised 
microcirculation—measured as perfused capillary density and proportion of per-
fused vessels—could not be weaned from VA-ECMO [32]. A separate study looking 
specifically at 28-day survival in cardiogenic shock patients placed on VA-ECMO, 
found that while MAP, pressor requirement and lactate did not differ, microcircula-
tion was better preserved in survivors compared to non-survivors within 12 hours 
of VA-ECMO support [33]. However, further research is needed to determine if 
microcirculatory assessment can help guide timing of VA-ECMO weaning.
5.3 Post VA-ECMO wean
Survival post VA-ECMO is predicated on correcting the underlying cause for 
shock or cardiac arrest, ultimately allowing device removal. However, weaning 
does not always signify that individuals will survive. Individual factors have to be 
considered to predict long term survival such as age, comorbidities, complications 
arising during circulatory support, underlying ventricular function and end organ 
function. On the latter, renal failure (signified by elevated creatinine level) or 
hepatic failure (marked by elevated total bilirubin and elevated INR) at the time 
of wean can impact short-term and long-term survival with multiorgan failure 
being the predominant mode of death after weaning [22]. If myocardial recovery 
is unlikely but other factors have been controlled and improved (including renal 
and hepatic function, lactate and resolution of pulmonary edema), durable VAD 
or heart transplantation should be taken into consideration, as longer duration on 
VA-ECMO can reduce the likelihood of survival to discharge or success towards a 
bridging option. In a small observational study, survival to discharge was higher for 
those transitioned within 14 days from VA-ECMO support to a VAD compared to 
those transitioned longer than 14 days (92 vs. 25%, p < 0.05) [34].
6. Weaning strategies
6.1 Pharmacological agents
The pharmacologic agents that have been used to assist with weaning trials 
have primarily been inotropic agents including dobutamine, epinephrine, dopa-
mine, milrinone and levosimendan. Epinephrine, dopamine and dobutamine 
are catecholamines, with epinephrine and dopamine having alpha-1 activity and 
thus some crossover with norepinephrine as vasoconstrictors. Dobutamine acts 
predominantly on beta-1 and beta-2 receptors. Milrinone and levosimendan on 
the other hand are inotropes without direct adrenergic receptor targets. Milrinone 
is a type-3 phosphodiesterase inhibitor and augments myocardial contraction by 
increasing intracellular concentrations of cAMP and calcium. Levosimendan on the 
other hand is a calcium sensitizer and is postulated to augment myocardial contrac-
tility without increasing intracellular calcium and myocardial oxygen consumption. 
Current evidence supports the use of both milrinone and levosimendan to assist 
with VA-ECMO weaning [35, 36].
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6.2 Weaning trials
Protocols for weaning VA-ECMO include:
1. A stepwise reduction in VA-ECMO flows either by percent of support or by 
0.5–1.0 L/min.
2. A pre-specified time interval in which the VA-ECMO flow is reduced for which 
can range from 10–15 min to 24 h.
3. Baseline parameter thresholds and subsequent measurements assessing for 
hemodynamic tolerance and myocardial adaptation to changes in preload and 
afterload as flows decrease.
4. Using continuous or intermittent transthoracic or transesophageal 
echocardiogram.
5. Frequency of weaning trials may occur daily, but typically occur 24–72 hours 
after VA-ECMO institution to allow for reversal and recovery from the inciting 
injury [29, 37–40].
In addition to requiring full anticoagulation during weaning trials, flows cannot 
be turned down below 1–1.5 L/min because of concerns for thrombus formation 
within the VA-ECMO circuit. Thus, clinicians must monitor changes in hemody-
namic and echocardiographic parameters as VA-ECMO flows are decreased and ter-
minate weaning if evidence of hemodynamic compromise or intolerance to preload 
changes such as loss of pulsatility, ventricular dysfunction or increases in filling 
pressures are seen. Hemodynamic tolerance during the weaning trial is extrapolated 
to imply myocardial recovery has occurred and that decannulation will be tolerated 
by the patient. In order to allow clinical assessments off VA-ECMO support entirely, 
some centers are using arteriovenous cannula bridging strategies that form a circuit 
that bypasses the patient [41], or a separate technique pioneered in neonates that 
reduces pump flow until the circuit runs retrograde [42, 43].
7. Proposed weaning protocol
Assessing the readiness for VA-ECMO weaning involves withdrawal or reversal 
of the inciting injury, maintenance or recovery of extracardiac organ function, 
and lastly myocardial recovery. Prior to weaning attempts, hemodynamic stability 
and adequate tissue perfusion defined as a MAP ≥ 60–65 mmHg while on mini-
mal pressor support, arterial pulsatility and lactate levels < 2 mmol/L should be 
achieved. VA-ECMO flow should be reduced by 0.5–1.0 L/min in 5–10-min intervals 
with continuous invasive hemodynamic and echocardiographic monitoring. In 
instances where adequate transthoracic windows cannot be achieved, transesopha-
geal echocardiogram should be performed, and biventricular size and function 
monitored. Because some parameters of left ventricular function including aortic 
VTI and TDSa are not easily obtained by both transthoracic and transesophageal 
echocardiography, we recommend measuring changes in ventricular size and visual 
assessments of ventricular function and valvular regurgitation. In instances where 
CVP rises to greater than 1518 mmHg (depending on ventilator settings) and the 
RV dilates with worsening function and tricuspid regurgitation, the weaning trial 
should be aborted. Left sided function and loading conditions may vary depending 
on venting strategies, however, in cases where PCWP rises above 20 mmHg and 
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arterial line pulsatility is lost due to LV dysfunction, isolated LV mechanical sup-
port should be considered. Prior to final decannulation in the operating room, the 
VA-ECMO speed should be left at 1.5 L/minutes for an hour to assess stability of 
hemodynamic, echocardiographic and tissue perfusion parameters.
8. Conclusion
VA-ECMO can rapidly stabilize patients and provide organ perfusion to those 
with refractory cardiogenic shock or cardiac arrest. Albeit associated with multiple 
complications that increase with longer duration of support, in the right patient it 
can improve the survival. Weaning strategies should be implemented as soon as the 
underlying condition has been corrected and improvement in metabolic, hepatic, 
pulmonary and renal function has occurred. Use of hemodynamic, echocardio-
graphic and serological markers of recovery should be taken into account prior and 
during each weaning trial to assess success of weaning or if need of VAD or heart 
transplantation should be considered.
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